Skip to Content

Anturol Approval History

  • FDA approved: Yes (First approved December 7th, 2011)
  • Brand name: Anturol
  • Generic name: oxybutynin
  • Dosage form: Gel
  • Company: Antares Pharma, Inc.
  • Treatment for: Overactive Bladder

Anturol (oxybutynin) is an anticholinergic transdermal gel formulation indicated for the management of overactive bladder.

Development History and FDA Approval Process for Anturol

Dec  8, 2011Approval Anturol Approved by FDA for the Treatment of Overactive Bladder
Apr  8, 2011Antares Pharma Announces FDA Acceptance of Anturol NDA for Filing
Dec 22, 2010Antares Pharma Announces Filing of New Drug Application for Anturol for Overactive Bladder

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.